Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact.
flow cytometry scores
iFS
myelodysplastic syndrome
Journal
Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
21
07
2021
received:
24
06
2021
accepted:
04
08
2021
pubmed:
15
8
2021
medline:
22
3
2023
entrez:
14
8
2021
Statut:
ppublish
Résumé
Flow cytometry (FCM) is a co-criterion in myelodysplastic syndromes (MDS) diagnostics according to the WHO classification. The presented study compared diagnostic power and prognostic impact of different FCM-based scores. A total of 807 bone marrow (BM) samples of patients with cytopenia (543 MDS, 153 non-clonal cytopenias, 111 non-MDS myeloid malignancies) and 78 healthy controls have been investigated using a standardized 8-color-FCM procedure. FCSS, Ogata-score, iFS, RED-score, and ELN-NEC were analyzed for sensitivity and specificity in comparison to standard diagnostic tools. Median follow up for patients was 26 month (range: 0.2-89). The iFS showed the highest accuracy (80%) with the best balance between sensitivity (79%) and specificity (86%). This was also valid in MDS with very low IPSS-R and even in MDS without ring sideroblasts, with normal blast count and karyotype, where iFS could confirm diagnosis in 62% and 65% of patients. Besides the high diagnostic power, the established iFS category "consistent with MDS" was associated with inferior overall survival (OS) independent from WHO classification (median: 51 month vs. not reached, p < 0.0001). Remarkably, this iFS category redefined a subgroup of patients with worse OS within IPSS-R low-risk category (73 month vs. not reached, p = 0.0433). Finally, multivariable analysis showed that iFS added independent prognostic information regarding OS besides IPSS-R. The iFS separates non-clonal cytopenias and MDS with the highest accuracy, provided information in addition to standard diagnostic procedures, and refined established prognostic tools for outcome prediction.
Sections du résumé
BACKGROUND
Flow cytometry (FCM) is a co-criterion in myelodysplastic syndromes (MDS) diagnostics according to the WHO classification. The presented study compared diagnostic power and prognostic impact of different FCM-based scores.
METHODS
A total of 807 bone marrow (BM) samples of patients with cytopenia (543 MDS, 153 non-clonal cytopenias, 111 non-MDS myeloid malignancies) and 78 healthy controls have been investigated using a standardized 8-color-FCM procedure. FCSS, Ogata-score, iFS, RED-score, and ELN-NEC were analyzed for sensitivity and specificity in comparison to standard diagnostic tools. Median follow up for patients was 26 month (range: 0.2-89).
RESULTS
The iFS showed the highest accuracy (80%) with the best balance between sensitivity (79%) and specificity (86%). This was also valid in MDS with very low IPSS-R and even in MDS without ring sideroblasts, with normal blast count and karyotype, where iFS could confirm diagnosis in 62% and 65% of patients. Besides the high diagnostic power, the established iFS category "consistent with MDS" was associated with inferior overall survival (OS) independent from WHO classification (median: 51 month vs. not reached, p < 0.0001). Remarkably, this iFS category redefined a subgroup of patients with worse OS within IPSS-R low-risk category (73 month vs. not reached, p = 0.0433). Finally, multivariable analysis showed that iFS added independent prognostic information regarding OS besides IPSS-R.
CONCLUSIONS
The iFS separates non-clonal cytopenias and MDS with the highest accuracy, provided information in addition to standard diagnostic procedures, and refined established prognostic tools for outcome prediction.
Identifiants
pubmed: 34390327
doi: 10.1002/cyto.b.22030
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-150Informations de copyright
© 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.
Références
Arber, A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-2405.
Barreau, S., Green, A. S., Dussiau, C., Alary, A.-S., Raimbault, A., Mathis, S., Willems, L., Bouscary, D., Kosmider, O., Bardet, V., Fontenay, M., & Chapuis, N. (2020). Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDS. Cytometry Part B: Clinical Cytometry, 98, 226-237.
Boddu, P., Garcia-Manero, G., Ravandi, F., Borthakur, G., Jabbour, E., DiNardo, C., Jain, N., Daver, N., Pemmaraju, N., Anderlini, P., Parmar, S., KC, D., Akosile, M., Pierce, S. A., Champlin, R., Cortes, J., Kantarjian, H., & Kadia, T. (2017). Clinical outcomes in adult patients with aplastic anemia: A single center experience. American Journal of Hematology, 92, 1295-1302.
Chu, S.-C., Wang, T.-F., Li, C.-C., Kao, R.-H., Li, D.-K., Su, Y.-C., Wells, D. A., & Loken, M. R. (2011). Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndrome. Leukemia Research, 35, 868-873.
Cremers, E. M. P., Westers, T. M., Alhan, C., Cali, C., Visser-Wisselaar, H. A., Chitu, D. A., van der Velden, V. H. J., te Marvelde, J. G., Klein, S. K., Muus, P., Vellenga, E., de Greef, G. E., Legdeur, M. C. C. J. C., Wijermans, P. W., Stevens-Kroef, M. J. P. L., Silva-Coelho, P. ., Jansen, J. H., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2017). Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica, 102, 320-326.
Davydova, Y. O., Parovichnikova, E. N., Galtseva, I. V., Kokhno, A. V., Dvirnyk, V. N., Kovrigina, A. M., Obukhova, T. N., Kapranov, N. M., Nikiforova, K. A., Glinkina, S. A., Troitskaya, V. V., Mikhailova, E. A., Fidarova, Z. T., Moiseeva, T. N., Lukina, E. A., Tsvetaeva, N. V., Nikulina, O. F., Kuzmina, L. A., & Savchenko, V. G. (2021). Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes. Cytometry Part B: Clinical Cytometry, 100, 312-321.
Della Porta, M. G., Malcovati, L., Boveri, E., Travaglino, E., Pietra, D., Pascutto, C., Passamonti, F., Invernizzi, R., Castello, A., Magrini, U., Lazzarino, M., & Cazzola, M. (2009). Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. Journal of Clinical Oncology, 27, 754-762.
Della Porta, M. G., Picone, C., Pascutto, C., Malcovati, L., Tamura, H., Handa, H., Czader, M., Freeman, S., Vyas, P., Porwit, A., Saft, L., Westers, T. M., Alhan, C., Cali, C., van de Loosdrecht, A. A., & Ogata, K. (2012). Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: Results of a European LeukemiaNET study. Haematologica, 97, 1209-1217.
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., le Beau, M. M., Slovak, M. L., … Haase, D. (2012). Revised international prognostic scoring system (IPSS-R) for of myelodysplastic syndromes. Blood, 120, 2454-2465.
Grille Montauban, S., Hernandez-Perez, C. R., Velloso, E. D. R. P., Novoa, V., Lorand-Metze, I., Gonzalez, J., Solari, L., Cismondi, V., Serrano, J. C., Burgnini, A., Rabelo-Carrasco, L. J., Bacal, N., Trias, N., Guevara, R., Vido, J. R., Crisp, R., Enrico, A., Boada, M., Pereira Cunha, F. G., … Lens, D. (2019). Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience. International Journal of Laboratory Hematology, 41, 536-541.
Kern, W., Haferlach, C., Schnittger, C., & Haferlach, T. (2010). Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome correlation to cytomorphology, cytogenetics, and clinical data. Cancer, 116, 4549-4563.
Mannelli, F., Bencini, S., Peruzzi, B., Guglielmelli, P., Pacilli, A., Rotunno, G., Gesullo, F., Jance, B., Bonetti, M., Caporale, R., Annunziato, F., & Vannucchi, A. M. (2019). Multi-lineage dysplasia assessment by immunophenotype in myeloproliferative neoplasms (MPN): Correlation with disease’ variant, clinical features and molecular genetics. Blood, 134(supplement_1), 1668.
Matarraz, S., Lopez, A., Barrena, S., Fernandez, C., Jensen, E., Flores-Montero, J., Rasillo, A., Sayagues, J. M., Sánchez, M. L., Bárcena, P., Hernandez-Rivas, J. M., Salvador, C., Fernandez-Mosteirín, N., Giralt, M., Perdiguer, L., Laranjeira, P., Paiva, A., & Orfao, A. (2010). Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognosis stratification of the disease: A pilot study on a series of 56 patients. Cytometry Part B: Clinical Cytometry, 78, 154-168.
Mathis, S., Chapuis, N., Debord, C., Rouquette, A., Radford-Weiss, I., Park, S., Dreyfus, F., Lacombe, C., Béné, M. C., Kosmider, O., Fontenay, M., & Bardet, V. (2013). Flow cytometric detection of dyserythropoiesis: A sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia, 27, 1981-1987.
Ogata, K., Della Porta, M., Malcovati, L., Picone, C., Yokose, N., Matsuda, A., Yamashita, T., Tamura, H., Tsukada, J., & Dan, K. (2009). Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: A prospective validation study. Haematologica, 94, 1066-1074.
Porwit, A., Oelschlaegel, U., Westers, T. M., Wagner-Ballon, O., Preijers, F., Bene, M. C., … van de Loosdrecht, A. A. (2021). Flow cytometry analysis in evaluation of myelodysplasia: Analytical issues. Recommendations from the international/European LeukemiaNet Working Group for Flow Cytometry in MDS. Cytometry Part B: Clinical Cytometry Manuscript submitted for publication.
Porwit, A., van de Loosdrecht, A. A., Bettelheim, P., Brodersen, L. E., Burbury, K., Béné, M. C., Cremers, E., Della Porta, M. G., Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F., Psarra, K., Subirá, D., Valent, P., van der Velden, V. H. J., Wells, D., … Kern, W. (2014). Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-Proposal from the international/European LeukemiaNet working Group for Flow Cytometry in MDS. Leukemia, 28, 1793-1798.
Schanz, J., Tüchler, H., Solé, F., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Valent, P., Giagounidis, A., Aul, C., Lübbert, M., Stauder, R., … Haase, D. (2012). New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30, 820-829.
Scott, B. L., Wells, D. A., Loken, M. R., Myerson, D., Leisenring, M., & Deeg, J. (2008). Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood, 112, 2681-2686.
Tiu, R. V., & Sekeres, M. A. (2014). Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. Current Opinion of Hematology, 21, 131-140.
Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., Giagounidis, A., Loken, M., Orfao, A., Lübbert, M., Ganser, A., Hofmann, W. K., Ogata, K., Schanz, J., Béné, M. C., … Bennett, J. M. (2017). Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 8, 73483-73500.
van de Loosdrecht, A. A., Alhan, C., Bene, M. C., Della Porta, M. G., Drager, A. M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C. H., Ireland, R., Jansen, J. H., Kern, W., Malcovati, L., te Marvelde, J. G., Mufti, G. J., Ogata, K., Orfao, A., Ossenkoppele, G. J., … Westers, T. M. (2009). Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica, 94, 1124-1134.
van de Loosdrecht, A. A., Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., … Ireland, R. (2021). Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet international MDS-flow Cytometry working group (ELN iMDS flow WG). Cytometry Part B: Clinical Cytometry Manuscript submitted for publication.
Van der Felden, V. H., Preijers, F., Johansson, U., Westers, T. M., Dunlop, A., Porwit, A., … van de Loosdrecht, A. A. (2021). Flow cytometry analysis of myelodysplasia: Pre-analytical and technical issues - recommendations from the international/European LeukemiaNet Working Group for Flow Cytometry in MDS. Cytometry Part B: Clinical Cytometry Manuscript submitted for publication.
Violidaki, D., Axler, O., Jafari, K., Bild, F., Nilsson, L., Mazur, L., Ehinger, M., & Porwit, A. (2020). Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes. Cytometry. Part B, Clinical Cytometry, 98, 399-411.
Wells, D. A., Benesch, M., Loken, M. R., Vallejo, C., Myerson, D., Leisenring, W. M., & Deeg, J. (2003). Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394-403.
Westers, T. M., Cremers, E. M. P., Oelschlaegel, U., Johansson, U., Bettelheim, P., Matarraz, S., Orfao, A., Moshaver, B., Brodersen, L. E., Loken, M. R., Wells, D. A., Subirá, D., Cullen, M., te Marvelde, J. G., van der Velden, V. H. J., Preijers, F. W. M. B., Chu, S. C., Feuillard, J., Guérin, E., … van de Loosdrecht, A. A. (2017). Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 102, 308-319.
Westers, T. M., Ireland, R., Kern, W., Alhan, C., Balleisen, J. S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J. A., Della Porta, M. G., Dräger, A. M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M. R., Malcovati, L., … van de Loosdrecht, A. A. (2012). Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet working group. Leukemia, 26, 1730-1741.